Abbott Agrees to $385 Million Settlement Over Baby Formula Plant Contamination Claims

The final signature on a $385 million settlement between Abbott Laboratories and the U.S. Department of Justice determines the financial accountability for the physical conditions that triggered a nationwide infant formula shortage. The agreement, finalized this week, resolves allegations that the company knowingly manufactured powdered formula in environments susceptible to contamination between January 2018 and December 2022. By securing this resolution, the government closes the book on a multi-year period where Abbott allegedly kept federal and state contracts flowing while conditions inside its plants deteriorated. The settlement specifically addresses claims that the company caused programs like Medicaid and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) to purchase formula that carried an unacceptable risk of microorganism contamination.[1][2]

Inside the Sturgis, Michigan, facility—the largest baby formula plant in the United States—the physical environment was far from the sterile ideal expected for infant nutrition. Federal prosecutors detailed a setting where roof leaks were a common occurrence, allowing water to run and drip directly over manufacturing equipment. Instead of executing permanent structural repairs, the company allegedly deployed temporary fixes like "roof leak umbrellas" to divert moisture away from the product processing areas. The Justice Department claims that Abbott corporate leadership understood the wet environment invited bacterial growth, yet allowed the conditions to persist while continuing to fulfill lucrative government contracts for powdered formula.[2][3]

The mechanical details of the operation showed similar signs of wear across the Sturgis site and a second facility in Casa Grande, Arizona. Liquid formula was transformed into dry powder using massive spray dryers that Abbott continued to operate even after documenting cracks and pits in the machinery. These physical defects created microscopic havens where bacteria could theoretically thrive, increasing the risk of contamination in products destined for vulnerable infants. Because WIC funds pay for more than half of all infant formula purchased in the United States, the government argued that these manufacturing shortcuts directly compromised the reliability and safety of taxpayer-funded nutrition programs.[2]

The financial breakdown of the settlement distributes the recovery across multiple levels of government that funded these purchases over the four-year period. Under the terms of the False Claims Act resolution, Abbott will pay $348.7 million to the federal government and an additional $36.3 million to participating states. The initial lawsuit was brought forward in 2022 by three former employees who worked in quality and maintenance operations at the company, providing firsthand accounts of the facility's physical deterioration.[1][2][4]

Under the whistleblower provisions of the False Claims Act, which allow private citizens to sue on behalf of the government when they witness fraud, those three individuals will share a $69 million portion of the federal recovery. Their intervention prompted the broader federal investigation that ultimately forced the company to address the structural failures at its plants. "No company should be gambling on the health and safety of our nation's infants by allowing unsanitary conditions to persist at a facility manufacturing baby formula," Associate Attorney General Stanley E. Woodward Jr. said in a statement announcing the resolution.[2][3]

The Justice Department noted that the settlement addresses the financial risk created by the manufacturing environment, though the government has officially closed its criminal investigation into the matter. The resolution follows a separate $670 million agreement Abbott reached earlier in the year to settle lawsuits alleging it hid the risk that its infant formula for premature babies could cause a deadly bowel disease. Together, these settlements represent a massive financial reckoning for the company's pediatric nutrition division, forcing a reevaluation of how operational risks are managed on the factory floor.[1][3]

The settlement does not include any admission of fault or liability from Abbott, and the company maintains that its products did not sicken children. The manufacturer emphasized that no unopened, distributed infant formula has ever tested positive for Cronobacter sakazakii, the bacterium at the center of the February 2022 recall. "Nothing matters more than the safety and quality of Abbott's products," the company stated in response to the finalized agreement. "We make infant formula with the same care we would for our own families and are deeply committed to earning and maintaining caregivers' trust." The company also noted that regulatory tests on unopened formula retrieved from homes during the recall returned negative results.[1][3]

The physical closure of the Sturgis plant in early 2022, following a Food and Drug Administration inspection that found unsanitary conditions and strains of Cronobacter on site, created a tangible crisis for parents across the country. That shutdown, combined with pandemic-era supply chain bottlenecks, emptied supermarket shelves and forced the Biden administration to invoke emergency rules and airlift formula from Europe. Today, Abbott operates the Sturgis facility under a consent decree that grants the FDA enhanced oversight for five years, ensuring the physical environment—from the roof to the spray dryers—maintains the rigorous standards required to feed the nation's infants.[1][2]